{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:53:16Z","timestamp":1788817996065,"version":"build-2803163510"},"reference-count":46,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,22]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>In patients with treatment-naive diffuse large B-cell lymphoma (DLBCL), the POLARIX study\u00a0(A\u00a0Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone [R-CHP] Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [R-CHOP] in Participants With Diffuse Large B-Cell Lymphoma) reported a 6.5% improvement in the 2-year progression-free survival (PFS), with no difference in overall survival (OS) or safety using polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) compared with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). We evaluated the cost-effectiveness of pola-R-CHP for DLBCL. We modeled a hypothetical cohort of US adults (mean age, 65 years) with treatment-naive DLBCL by developing a Markov model (lifetime horizon) to model the cost-effectiveness of pola-R-CHP and R-CHOP using a range of plausible long-term outcomes. Progression rates and OS were estimated from POLARIX. Outcome measures were reported in incremental cost-effectiveness ratios, with a willingness-to-pay (WTP) threshold of $150\u2009000 per quality-adjusted life-year (QALY). Assuming a 5-year PFS of 69.6% with pola-R-CHP and 62.7% with R-CHOP, pola-R-CHP was cost-effective at a WTP of $150\u2009000 (incremental cost-effectiveness ratio, $84\u2009308\/QALY). pola-R-CHP was no longer cost-effective if its 5-year PFS was 66.1% or\u00a0lower. One-way sensitivity analysis revealed that pola-R-CHP is cost-effective up to a cost of $276\u2009312 at a WTP of $150\u2009000. pola-R-CHP was the cost-effective strategy in 56.6% of the 10\u2009000 Monte Carlo iterations at a WTP of $150\u2009000. If the absolute benefit in PFS is maintained over time, pola-R-CHP is cost-effective compared with R-CHOP at a WTP of $150\u2009000\/QALY. However, its cost-effectiveness is highly dependent on its long-term outcomes and costs of chimeric antigen receptor T-cell therapy. Routine usage of pola-R-CHP would add significantly to health care expenditures. Price reductions or identification of subgroups that have maximal benefit would improve cost-effectiveness.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2022016624","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T19:22:40Z","timestamp":1655234560000},"page":"2697-2708","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma"],"prefix":"10.1182","volume":"140","author":[{"given":"Swetha Kambhampati","family":"Thiruvengadam","sequence":"first","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Saumoy","sequence":"additional","affiliation":[{"name":"2Center for Digestive Health, Penn Medicine Princeton Medical Center, Plainsboro, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yecheskel","family":"Schneider","sequence":"additional","affiliation":[{"name":"3St. Luke\u2019s University Health Network, Bethlehem, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Pak","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1464-5494","authenticated-orcid":false,"given":"Lihua Elizabeth","family":"Budde","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G.","family":"Mei","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5292-8298","authenticated-orcid":false,"given":"Tanya","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8418-2811","authenticated-orcid":false,"given":"Leslie L.","family":"Popplewell","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ping","family":"Wen","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4308-629X","authenticated-orcid":false,"given":"Jasmine","family":"Zain","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry W.","family":"Kwak","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Rosen","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey V.","family":"Danilov","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-7415","authenticated-orcid":false,"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil R.","family":"Thiruvengadam","sequence":"additional","affiliation":[{"name":"4Division of Gastroenterology and Hepatology, Loma Linda University Health, Loma Linda, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2025041413164518000_bib1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","article-title":"Diffuse large B-cell lymphoma: R-CHOP failure\u2014what to do?","volume":"2016","author":"Coiffier","year":"2016","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"16","key":"2025041413164518000_bib2","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1182\/blood-2015-03-632430","article-title":"Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL","volume":"126","author":"Offner","year":"2015","journal-title":"Blood"},{"issue":"13","key":"2025041413164518000_bib3","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2217\/fon-2016-0130","article-title":"ROBUST: lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma","volume":"12","author":"Nowakowski","year":"2016","journal-title":"Future Oncol"},{"issue":"15","key":"2025041413164518000_bib4","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"2025041413164518000_bib5","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s40265-019-01175-0","article-title":"Polatuzumab vedotin: first global approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"issue":"2","key":"2025041413164518000_bib6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2025041413164518000_bib7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2025041413164518000_bib8","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1524-4733.2005.00037.x","article-title":"Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma","volume":"8","author":"Best","year":"2005","journal-title":"Value Health"},{"issue":"8","key":"2025041413164518000_bib9","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/cncr.20956","article-title":"Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma","volume":"103","author":"Hornberger","year":"2005","journal-title":"Cancer"},{"issue":"1","key":"2025041413164518000_bib10","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1186\/1471-2407-14-586","article-title":"Real world costs and cost-effectiveness of rituximab for diffuse large B-cell lymphoma patients: a population-based analysis","volume":"14","author":"Khor","year":"2014","journal-title":"BMC Cancer"},{"issue":"24","key":"2025041413164518000_bib11","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma","volume":"37","author":"Lin","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2025041413164518000_bib12","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"12","key":"2025041413164518000_bib13","first-page":"1","article-title":"United States life tables, 2018","volume":"69","author":"Arias","year":"2020","journal-title":"Natl Vital Stat Rep"},{"issue":"suppl 5","key":"2025041413164518000_bib14","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"issue":"6","key":"2025041413164518000_bib15","doi-asserted-by":"crossref","first-page":"650","DOI":"10.6004\/jnccn.2019.0029","article-title":"NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019","volume":"17","author":"Zelenetz","year":"2019","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"16","key":"2025041413164518000_bib16","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2025041413164518000_bib17","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1182\/blood-2021-148078","article-title":"Long-term (\u22654 year and \u22655 year) overall survival (OS) by 12- and 24-month event-free survival (EFS): an updated analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients (pts) with refractory large B-cell lymphoma (LBCL)","volume":"138","author":"Jacobson","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2025041413164518000_bib18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"26","key":"2025041413164518000_bib19","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2025041413164518000_bib20","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1080\/10428194.2018.1459613","article-title":"Costs of relapsed diffuse large B-cell lymphoma among Medicare patients","volume":"59","author":"Huntington","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2025041413164518000_bib21","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2010.08549.x","article-title":"The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls","volume":"152","author":"Hill","year":"2011","journal-title":"Br J Haematol"},{"issue":"10","key":"2025041413164518000_bib22","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2025041413164518000_bib23","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1177\/0272989X19875950","article-title":"An evaluation of survival curve extrapolation techniques using long-term observational cancer data","volume":"39","author":"Vickers","year":"2019","journal-title":"Med Decis Making"},{"issue":"3","key":"2025041413164518000_bib24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/0272989X12475091","article-title":"The \u201chazards\u201d of extrapolating survival curves","volume":"33","author":"Davies","year":"2013","journal-title":"Med Decis Making"},{"issue":"12","key":"2025041413164518000_bib25","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"2025041413164518000_bib26","unstructured":"Micromedex: Red Book online. Available at:. https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian. Accessed 22 January 2022."},{"key":"2025041413164518000_bib27","unstructured":"Agency for Healthcare Research and Quality: Healthcare Cost and Utilization Project (HCUP). Available at:. https:\/\/www.ahrq.gov\/data\/hcup\/index.html. Accessed 22 January 2022."},{"key":"2025041413164518000_bib28","unstructured":"Centers for Medicare & Medicaid Services: Physician fee schedule. Available at:. https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/PFSLookup\/index.html. Accessed 14 January 2022."},{"key":"2025041413164518000_bib29","unstructured":"Agency for Healthcare Research and Quality: Nationwide HCUP databases. Accessed at:. https:\/\/www.hcup-us.ahrq.gov\/databases.jsp. Date Accessed: 01\/22\/2022."},{"issue":"25","key":"2025041413164518000_bib30","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.2217\/fon-2018-0267","article-title":"Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA","volume":"14","author":"Morrison","year":"2018","journal-title":"Future Oncol"},{"issue":"14","key":"2025041413164518000_bib31","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1080\/10428194.2020.1808208","article-title":"Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"61","author":"Patel","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2025041413164518000_bib32","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1600-0609.2005.00438.x","article-title":"Self-reported quality of life in elderly patients with aggressive non-Hodgkin\u2019s lymphoma treated with CHOP chemotherapy","volume":"75","author":"Doorduijn","year":"2005","journal-title":"Eur J Haematol"},{"issue":"4","key":"2025041413164518000_bib33","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/14737167.2020.1779063","article-title":"Incremental cost-effectiveness analysis of tyrosine kinase inhibitors in advanced non-small cell lung cancer with mutations of the epidermal growth factor receptor in Colombia","volume":"21","author":"Lasalvia","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"7","key":"2025041413164518000_bib34","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jval.2020.04.1825","article-title":"EQ-5D-derived health state utility values in hematologic malignancies: a catalog of 796 utilities based on a systematic review","volume":"23","author":"Golicki","year":"2020","journal-title":"Value Health"},{"issue":"11","key":"2025041413164518000_bib35","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2165\/00019053-200119110-00003","article-title":"Cost effectiveness of treatment options in advanced breast cancer in the UK","volume":"19","author":"Brown","year":"2001","journal-title":"PharmacoEconomics"},{"issue":"2","key":"2025041413164518000_bib36","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2471\/BLT.14.138206","article-title":"Thresholds for the cost-effectiveness of interventions: alternative approaches","volume":"93","author":"Marseille","year":"2015","journal-title":"Bull World Health Organ"},{"issue":"7","key":"2025041413164518000_bib37","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10343","key":"2025041413164518000_bib38","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase\u00a03 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"2025041413164518000_bib39","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1200\/JCO.2009.24.5860","article-title":"Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome","volume":"28","author":"Larouche","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"2025041413164518000_bib40","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1200\/JCO.19.00014","article-title":"Late relapses in\u00a0patients with diffuse largeB-cell lymphoma treated with immunochemotherapy","volume":"37","author":"Wang","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2025041413164518000_bib41","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2016.70.0765","article-title":"Minimal loss of lifetime for patients with diffuse large B-cell lymphoma in remission and event free 24 months after treatment: a Danish population-based study","volume":"35","author":"Jakobsen","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2025041413164518000_bib42","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","article-title":"Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025","volume":"63","author":"Kanas","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2025041413164518000_bib43","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2217\/cer-2018-0094","article-title":"Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA","volume":"8","author":"Ren","year":"2019","journal-title":"J\u00a0Comp Eff Res"},{"issue":"6","key":"2025041413164518000_bib44","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1524-4733.2010.00737.x","article-title":"Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada","volume":"13","author":"Johnston","year":"2010","journal-title":"Value Health"},{"issue":"7","key":"2025041413164518000_bib45","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1080\/10428194.2017.1390230","article-title":"Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma","volume":"59","author":"Chen","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2025041413164518000_bib46","doi-asserted-by":"crossref","first-page":"E3553","DOI":"10.3390\/cancers12123553","article-title":"Molecular genetics of relapsed diffuse large B-cell lymphoma: insight into mechanisms of therapy resistance","volume":"12","author":"Berendsen","year":"2020","journal-title":"Cancers (Basel)"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/25\/2697\/2025484\/blood_bld-2022-016624-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/25\/2697\/2025484\/blood_bld-2022-016624-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T13:16:57Z","timestamp":1744636617000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/25\/2697\/485545\/Cost-effectiveness-of-polatuzumab-vedotin-combined"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":46,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2022,12,22]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022016624","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]}}}